In today’s briefing:
- REVB: New Market Potential and Quarterly Results
- Shionogi & Co (4507 JP): Torii Acquisition to Broaden Portfolio; High R&D to Dent Profitability
- Charm Care Corp (6062 JP): Q3 FY06/25 flash update
- LGVN: Setting Up for a Pivotal Year
REVB: New Market Potential and Quarterly Results
- Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system.
- The company announced its 1Q2025 financial results after recently revealing that it is targeting a new target indication with its Gemini treatment, the prevention of infection in burn patients.
Shionogi & Co (4507 JP): Torii Acquisition to Broaden Portfolio; High R&D to Dent Profitability
- Shionogi & Co (4507 JP) is acquiring Torii Pharmaceutical, as well as the pharmaceutical business of Japan Tobacco and U.S. group company Akros Pharma (sub-subsidiary of Japan Tobacco) for ~¥160B.
- With minimum overlap in focus areas, Shionogi believes that the transaction will create a leading company that delivers innovative pharmaceuticals. However, R&D expenses of the combined company will remain elevated.
- Considering the promising pipeline, we are hopeful on the long-term growth prospect of the combined company. Shionogi is scheduled to announce FY25 result on May 12.
Charm Care Corp (6062 JP): Q3 FY06/25 flash update
- Revenue increased by 2.5% YoY to JPY30.3bn, with operating profit up 1.0% YoY to JPY2.5bn.
- Occupancy rates at existing assisted-living facilities averaged 94.4%, with LIKE facilities at 99.3% in cumulative Q3.
- Good Partners’ revenue and profit were strong, with a 45.5% YoY revenue increase to JPY2.0bn, including internal revenue.
LGVN: Setting Up for a Pivotal Year
- Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer’s Disease.
- The company announced its 1Q results that illustrate the company is on the verge of potentially transformational year.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
